Analysis of drugs-based treatment methods for Alzheimer’s disease

Alzheimer’s disease (AD) treatment is one of the focuses of current medical research. Researchers have made progress in exploring the pathogenesis and treatment for AD, especially with disease-modifying therapies, cognitive enhancers, and medications for neuropsychiatric symptoms. However, there is still a research gap on how to effectively combine these drugs to improve the quality of life for AD patients. Therefore, this research aims to explore the effects of three drugs on AD, including lecanemab, brexpiprazole, and donepezil. This research systematically analyzed the efficacy of three drugs in different aspects of the disease: lecanemab as a disease-modifying therapy, brexpiprazole for relieving agitated symptoms, and donepezil for improving cognitive function. Through the analysis of their action mechanisms and clinical trial data, this research reveals the different roles of these drugs in AD treatment. The research results indicate that the combination of these three drugs can improve patients' symptoms from different aspects. Because of the various pathological mechanisms of AD, individualized multi-drug combination therapy may be an effective direction for future treatment.